J. Kim

SRC Activation Drives Acquired Pemetrexed Resistance in Non‐Small Cell Lung Cancer and Is Targetable by Dasatinib

Pemetrexed, a standard antifolate chemotherapy for non‐squamous non‐small cell lung cancer (NSCLC), is often limited by acquired resistance. We investigated whether SRC kinase mediates pemetrexed resistance and whether SRC inhibition can suppress survival signaling in pemetrexed‐resistant NSCLC cells.